Form 4: Castle Biosciences CEO Reports Routine Stock Transactions

Castle Biosciences CEO Derek Maetzold reported the vesting of restricted stock units and subsequent acquisition of common stock, alongside tax-related dispositions.

Summary

• Derek J. Maetzold, President & Chief Executive Officer and Director of Castle Biosciences Inc. (CSTL), reported multiple transactions involving the company's common stock.
• On December 9, 2025, Mr. Maetzold acquired 33,495 shares of common stock through the vesting of Restricted Stock Units (RSUs) and disposed of 13,181 shares at a price of $38.25 for tax withholding purposes.
• Following these transactions on December 9, 2025, his direct beneficial ownership of common stock was 57,861 shares.
• On December 10, 2025, Mr. Maetzold acquired an additional 15,424 shares of common stock from RSU vesting and disposed of 6,070 shares at a price of $38.02 for tax withholding.
• After all reported transactions, Mr. Maetzold's direct beneficial ownership of common stock stands at 67,215 shares.
• He also holds significant indirect beneficial ownership through various trusts, totaling 261,385 shares across nine different trusts, including The Maetzold Descendants 2020 Trust (52,923 shares), Derek Maetzold 2020 Irrevocable Trust (44,986 shares), and several DJM Grantor Retained Annuity Trusts (totaling 148,900 shares).

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions involving the vesting of Restricted Stock Units and subsequent tax-related sales. While there's a net increase in direct beneficial ownership, these are expected compensation events and do not signal new strategic or operational developments, leading to a neutral to slightly positive sentiment.

Positives

• The transactions resulted in a net increase in Derek Maetzold's direct beneficial ownership of Castle Biosciences common stock after accounting for tax withholdings, indicating continued alignment with shareholder interests.
• The vesting of Restricted Stock Units represents the successful achievement of previously set compensation milestones.

Negatives

• A portion of the acquired shares was disposed of to cover tax obligations, which is a routine but necessary sale of company stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions and does not provide information directly related to broader industry trends or competitive landscape.

Key Dates

Recommendation

This Form 4 details routine RSU vesting and tax-related stock dispositions by a key executive. Such transactions are part of standard compensation and do not typically provide new material information about the company's operational performance or future prospects that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals.

Keywords

Castle Biosciences, CSTL, Form 4, insider transaction, RSU vesting, stock ownership, Derek Maetzold